bioRxiv Science⌕ Search

Biology subjects

Nazo, N.

Publications and source records attributed to Nazo, N..

2 recordsLinked to original sources

Endothelial beta-arrestins Regulate Mechanotransduction by the Type II Bone Morphogenetic Protein Receptor in Primary Cilia

RationaleModulation of endothelial cell behavior and phenotype by hemodynamic forces involves many signaling components, including cell surface receptors, intracellular signaling intermediaries, transcription factors, and epigenetic elements. Many of the signaling mechanisms that underlie mechanotransduction by endothelial cells are inadequately defined. ObjectiveWe sought to better understand how {beta}-arrestins, intracellular proteins that regulate agonist-mediated desensitization and integration of signaling by transmembrane receptors, may be involved in the endothelial cell response to shear stress. Methods and ResultsIn vitro studies with primary endothelial cells subjected to {beta}-arrestin knockdown, and in vivo studies using mice with endothelial specific deletion of {beta}-arrestin 1 and {beta}-arrestin 2 were conducted. We found that {beta}-arrestins are localized to primary cilia in endothelial cells, which are present in subpopulations of endothelial cells in relatively low shear states. Recruitment of {beta}-arrestins to cilia involved its interaction with IFT81, a component of the flagellar transport protein complex in the cilia. {beta}-arrestin knockdown led to marked reduction in shear stress response, including induction of NOS3 expression. Within the cilia, {beta}-arrestins were found to associate with the type II bone morphogenetic protein receptor (BMPR-II), whose disruption similarly led to an impaired endothelial shear response. {beta}-arrestins also regulated Smad transcription factor phosphorylation by BMPR-II. Mice with endothelial specific deletion of {beta}-arrestin 1 and {beta}-arrestin 2 were found to have impaired retinal angiogenesis. ConclusionWe have identified a novel role for endothelial {beta}-arrestins as key transducers of ciliary mechanotransduction that play a central role in shear signaling by BMPR-II and contribute to vascular development. NOVELTY AND SIGNIFICANCE What Is Known?O_LIEndothelial cells respond to flow-induced shear stress with biochemical changes, such as phosphorylation of endothelial nitric oxide synthase, that promote morphological changes, such as cell alignment. C_LIO_LIThe endothelial response to shear stress can involve primary cilia, microtubule-based sensory organelles that detect extracellular stimuli and generates intracellular signals. C_LIO_LIThe specific ciliary signaling pathways that regulate endothelial mechanotransduction have not been fully elucidated. C_LI What New Information Does This Article Contribute?O_LI{beta}-arrestins directly interact with the ciliary protein intraflagellar transport protein 81 (IFT81), which is present in the primary cilia of endothelial cells, and are required for the morphological response to flow-induced shear stress. C_LIO_LI{beta}-arrestins regulates type II bone morphogenetic protein receptor signaling, which is required for the endothelial response to shear stress, and is required for the phosphorylation of Smad transcription factors. C_LIO_LI{beta}-arrestins are required for endothelial nitric oxide synthase-mediated flow-induced shear stress response in endothelial cells. C_LIO_LIEndothelial cell-specific knockout of {beta}-arrestins results in abnormal vascular development, with a loss of vessel length and branchpoints. C_LI

molecular biology↗

Single-Cell Analysis Identifies Distinct Immune and Smooth Muscle Cell Populations that Contribute to Chronic Thromboembolic Pulmonary Hypertension

Chronic thromboembolic pulmonary hypertension (CTEPH) is a sequelae of acute pulmonary embolism (PE) in which the PE remodels into a chronic scar in the pulmonary arteries. This results in vascular obstruction, small vessel arteriopathy and pulmonary hypertension. Our current understanding of CTEPH pathobiology is primarily derived from cell-based studies limited by the use of specific cell markers or phenotypic modulation in cell culture. Here we used single cell RNA sequencing (scRNAseq) of tissue removed at the time of pulmonary thromboendarterectomy (PTE) surgery to identify the multiple cell types, including macrophages, T cells, and smooth muscle cells, that comprise CTEPH thrombus. Notably, multiple macrophage subclusters were identified but broadly split into two categories, with the larger group characterized by an upregulation of inflammatory signaling predicted to promote pulmonary vascular remodeling. Both CD4+ and CD8+ T cells were identified and likely contribute to chronic inflammation in CTEPH. Smooth muscle cells were a heterogeneous population, with a cluster of myofibroblasts that express markers of fibrosis and are predicted to arise from other smooth muscle cell clusters based on pseudotime analysis. Additionally, cultured endothelial, smooth muscle and myofibroblast cells isolated from CTEPH thrombus have distinct phenotypes from control cells with regards to angiogenic potential and rates of proliferation and apoptosis. Lastly, our analysis identified protease-activated receptor 1 (PAR1) as a potential therapeutic target that links thrombosis to chronic PE in CTEPH, with PAR1 inhibition decreasing smooth muscle cell and myofibroblast proliferation and migration. These findings suggest a model for CTEPH similar to atherosclerosis, with chronic inflammation promoted by macrophages and T cells driving vascular remodeling through smooth muscle cell modulation, and suggest new approaches for pharmacologically targeting this disease.

pathology↗